These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 22829689)

  • 1. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.
    Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV
    Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of health care costs and utilization patterns for patients with gout.
    Park H; Rascati KL; Prasla K; McBayne T
    Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in the management of gout.
    Keith MP; Gilliland WR
    Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis.
    Ferraz MB; O'Brien B
    J Rheumatol; 1995 May; 22(5):908-14. PubMed ID: 8587081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks.
    Lynch W; Chan W; Kleinman N; Andrews LM; Yadao AM
    Popul Health Manag; 2013 Apr; 16(2):138-45. PubMed ID: 23113634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gouty arthritis: understanding the disease state and management options in primary care.
    Sunkureddi P
    Adv Ther; 2011 Sep; 28(9):748-60. PubMed ID: 21894471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.
    Halpern R; Fuldeore MJ; Mody RR; Patel PA; Mikuls TR
    J Clin Rheumatol; 2009 Feb; 15(1):3-7. PubMed ID: 19125135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
    Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
    J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
    Wu EQ; Patel PA; Mody RR; Yu AP; Cahill KE; Tang J; Krishnan E
    J Rheumatol; 2009 May; 36(5):1032-40. PubMed ID: 19369467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new perspective on the pharmacoeconomics of colchicine.
    Wertheimer AI; Davis MW; Lauterio TJ
    Curr Med Res Opin; 2011 May; 27(5):931-7. PubMed ID: 21370937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
    Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
    J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in health care resource utilization associated with extended-release theophylline.
    Schulz RM; Yates WN
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):267-72. PubMed ID: 10094217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of hyperuricemia and gout].
    Pöllmann G; Kullich W; Klein G
    Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions.
    Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R
    Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical practice. Gout.
    Terkeltaub RA
    N Engl J Med; 2003 Oct; 349(17):1647-55. PubMed ID: 14573737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.